Atossa Therapeutics (NASDAQ:ATOS - Get Free Report) is scheduled to be issuing its quarterly earnings data on Wednesday, March 20th.
Atossa Therapeutics Price Performance
Shares of NASDAQ:ATOS traded up $0.26 on Tuesday, hitting $1.55. The company's stock had a trading volume of 4,580,674 shares, compared to its average volume of 674,002. The company has a 50-day simple moving average of $0.97 and a 200 day simple moving average of $0.83. Atossa Therapeutics has a 1 year low of $0.59 and a 1 year high of $1.57. The company has a market capitalization of $194.22 million, a PE ratio of -6.21 and a beta of 1.16.
Analyst Ratings Changes
Several analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Atossa Therapeutics in a report on Friday, January 12th. StockNews.com cut Atossa Therapeutics from a "hold" rating to a "sell" rating in a report on Monday. Finally, HC Wainwright reiterated a "buy" rating and set a $4.00 price objective on shares of Atossa Therapeutics in a research report on Monday, February 12th.
View Our Latest Analysis on ATOS
Institutional Investors Weigh In On Atossa Therapeutics
A number of large investors have recently made changes to their positions in the business. UBS Group AG purchased a new position in shares of Atossa Therapeutics in the 3rd quarter valued at approximately $25,000. First Republic Investment Management Inc. lifted its holdings in shares of Atossa Therapeutics by 79.8% during the first quarter. First Republic Investment Management Inc. now owns 25,167 shares of the company's stock valued at $31,000 after purchasing an additional 11,167 shares in the last quarter. Two Sigma Securities LLC bought a new position in Atossa Therapeutics in the second quarter valued at about $32,000. XTX Topco Ltd bought a new position in Atossa Therapeutics in the second quarter valued at about $50,000. Finally, LPL Financial LLC bought a new position in Atossa Therapeutics in the second quarter valued at about $59,000. 12.74% of the stock is currently owned by institutional investors.
Atossa Therapeutics Company Profile
(
Get Free Report)
Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.
Featured Articles
Before you consider Atossa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Atossa Therapeutics wasn't on the list.
While Atossa Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
